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Abstract
The vertebrate immune system is a wonder of modern evolution. Occasionally, how-
ever, correlations within the immune system lead to inappropriate recruitment of
preexisting T cells against novel viral diseases. We present a random energy the-
ory for the correlations in the naive and memory T cell immune responses. The
non-linear susceptibility of the random energy model to structural changes captures
the correlations in the immune response to mutated antigens. We show how the
sequence-level diversity of the T cell repertoire drives the dynamics of the immune
response against mutated viral antigens.
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1 Introduction
In this work, we develop a random energy model that allows us to address
limitations in the cellular immune system response to mutable viral diseases.
We focus on the T cell response, with an emphasis on cytotoxic lympho-
cyte (CTL) T cells, which bind the peptide-major histocompatability class I
(MHCI) complex [1]. These T cells eradicate other infected cells through an
interaction mediated by the binding of the T cell receptor (TCR) to antigenic
peptides derived from the infectious disease. The finite number of different T
cells within an individual and the existence of immune system memory makes
the immune system response to mutating viral diseases nontrivial. We seek
to understand how the T cell receptor repertoire changes within the immune
system in response to repeated exposure to evolving viral diseases.
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The immune system has a mechanism for selecting among the many possible
TCRs those that best bind to the antigenic peptides. TCRs are constructed
from modular elements, and each individual has an approximate diversity of
2.5 × 107 different receptors [2]. TCRs undergo rounds of selection for in-
creased affinity [3]. TCRs do not undergo any further mutation during the
immune response. Those TCRs that are stochastically selected in the primary
response to a disease become memory cells [4]. While many details affect the
T cell selection process [5,6], selection for increased affinity is thought to be a
dominant factor [7].
Several limitations of the cellular immune system have been reported that
stem from the fact that a single T cell receptor may bind multiple antigenic
peptides. This cross-reactivity is studied in quantitative molecular experiments
through the use of altered peptide ligands (APLs), peptides that differ from
the native ligand of the TCR by one amino acid [8]. We here develop a theory
of the T cell response to altered peptide ligands. In section 2, we introduce the
random energy model of the interaction between the TCR and the peptide-
MHC complex. In section 3, we describe the process by which T cells that
bind antigen are selected. In section 4, we show how experiments with altered
peptide ligands may be understood with the random energy model. We discuss
a critical point in the immune response probability in section 5. In section 6,
we discuss correlations that may arise in forward and reverse experiments with
altered peptide ligands. We conclude in section 7.
2 The Random Energy Model
The important molecular components of the T cell recognition event are the
peptide-MHCI complex and the T cell receptor (TCR), as shown in Figure 1.
Typically, the peptide ligand is on the order of 9 amino acids long. The TCR
variable region is composed of 54 amino acids, grouped into 6 subdomains.
The TCR sits atop the peptide-MHCI complex during recognition. Recogni-
tion of specific immunogenic peptides is due to the interaction between the
subdomains of the TCR and the peptide. The majority of the amino acids
in the peptide are directly recognized by 1–4 amino acids of the TCR, with
typically 3 amino acids in the peptide being hot spots of the binding [9]. The
entire TCR variable region interacts relatively non-specifically with the MHCI
complex. There is also a relatively generic interaction between the peptide and
the MHCI complex.
There are too many atoms within the TCR-peptide-MHCI complex and too
many TCRs within an individual to treat this problem in full atomistic detail.
We therefore use a type of random energy model to represent the interactions
between the TCR, peptide, and MHCI complex. This random energy builds
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a hierarchy of correlations into Derrida’s random energy theory [10]. The im-
mune system being a real-time example of an evolving system, the random
energy approach is a natural one [11]. Our random energy model is a gener-
alization of Kauffman’s NK model [12] to include correlations due to protein
secondary structure [13,14]. The model introduced here to account for the T
cell immune response contains an additional term relative to that which de-
scribes the B cell immune response [15]. In detail, our generalized NK model
for the T cell response considers four different kinds of interactions: interac-
tion within a subdomain of the TCR (U sd), interactions between subdomains
of the TCR (U sd−sd), indirect interactions between the TCR and the peptide
(Upep−sd), and direct binding interaction between the TCR and peptide (U c).
In this model, interactions between the peptide or TCR and the MHCI have
been integrated out. As is typical in statistical mechanics [16], integrating
out these terms produces random interactions in the Hamiltonian, and we as-
sume these to be roughly of the form of the other intermolecular terms in our
model. In the altered peptide ligand experiments considered here, the pep-
tides, whether original or altered, are typically expressed by the same MHCI.
The first three terms of the present random energy model are identical to
those used to model protein evolution [14] and the B cell antibody response
[15]. The parameters within the model have been determined either by earlier
work [12,13] or by structural biology [14]. The energy function of the TCR
with peptide-MHCI is
U =
M∑
i=1
U sdαi +
M∑
i>j=1
U sd−sdij +
M∑
i=1
Upep−sdi +
Nb∑
i=1
NCON∑
j=1
U cij , (1)
whereM = 6 is the number of TCR secondary structural subdomains, Nb = 3
is the number of hot-spot amino acids that directly bind to the TCR, and
NCON = 3 is the number of T cell amino acids contributing directly to the
binding of each peptide amino acid. The subdomain energy U sd is
U sdαi =
1√
M(N −K + 1)
N−K+1∑
j=1
σαi(aj , aj+1, · · ·, aj+K−1) , (2)
where N = 9 is the number of amino acids in a subdomain, and K = 4 is the
range of local interaction within a subdomain. The prefactor for this term, and
the other three terms in Eq. 1, is chosen so that random sequences produce a
unit variance of this term. Thus, each term in Eq. 1 contributes roughly equal
weight, a priori. All subdomains belong to one of L = 5 different types (e.g.,
helices, strands, loops, turns, and others). The quenched Gaussian random
number σαi is different for each value of its argument for a given subdomain
type, αi. All σ values in the model are Gaussian random numbers and have
zero mean and unit variance. The sigma values are different for each value
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of the argument, subscript, or superscript. The variable αi defines the type
of secondary structure for the ith subdomain, 1 ≤ αi ≤ L. The energy of
interaction between secondary structures is
U sd−sdij =
√
2
DM(M − 1)
×
D∑
k=1
σkij(a
i
j1 , · · ·, aijK/2; a
j
jK/2+1
, · · ·, ajjK) .
(3)
We set the number of interactions between secondary structures at D = 2,
as the TCR-peptide-MHCI interaction is a slightly less rough than is the
antibody-antigen interaction landscape where we have used D = 6 [15]. Here
σkij and the interacting amino acids, j1, · · ·, jK , are selected at random for each
interaction (i, j, k). The indirect interaction energy between the peptide and
the TCR is given by
Upep−sdi =
√
1
DM
D∑
k=1
σki (a
pep
j1 , · · ·, apepjK/2; aijK/2+1, · · ·, aijK) . (4)
Here σki and the interacting amino acids, j1, · · ·, jK , are selected at random
in the peptide and TCR subdomain for each interaction (i, k). The chemical
binding energy of each TCR amino acid to the peptide is given by
U cij =
1√
NbNCON
σij(a
pep
j1 , aj2) . (5)
The contributing amino acids, j1, j2, and the unit-normal weight of the bind-
ing, σij , are chosen at random for each interaction (i, j), with Nb possible
values for j1, and NM possible values for j2.
Although there are 20 different naturally occurring amino acids, there are only
roughly five distinct classes. Mutations that change an amino acid to another
within the same class are termed conservative, whereas mutations that change
the class of the amino acid are termed non-conservative. This distinction is
significant because non-conservative mutations change the energy landscape
more dramatically than do conservative mutations. Non-conservative muta-
tions lead to a factor of 2.34 ≈ (1+1/22)1/2/(1/2) greater energy change than
do conservative mutations, on average as estimated from statistically deter-
mined energy values from the protein sequence alignment matrix (PAM) [17].
To consider all 20 amino acids within the random energy model, Eq. 1, and to
consider the differing effects of conservative and non-conservative mutations,
we set the random σ for amino acid i that belongs to group j as σ = wj+wi/2,
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where the w are Gaussian random numbers with zero average and unit stan-
dard deviation. There are 5 groups, with 8 amino acids in the neutral and
polar plus cystein group, 2 amino acids in the negative and polar group, 3
amino acids in the positive and polar group, 4 amino acids in the nonpolar
without ring group, and 3 amino acids in the nonpolar with ring group. The
results are not greatly sensitive to the precise groupings of the amino acids.
The naive TCR repertoire is generated randomly from gene fragments. This is
accomplished by constructing the TCRs from subdomain pools. Fragments for
each of the L subdomain types are chosen randomly from 5 of the 100 lowest
energy subdomain sequences. This diversity mimics the known TCR diversity,
(5×L)M ≈ 108. There have been recent suggestions that the possible diversity
of a given individual’s TCR repertoire is ≈ 1011, with the actual diversity
expressed at any point in time being ≈ 108 [18]. These numbers, which are
very much in line with the numbers for human antibodies, would imply L = 13.
The results for the present study are not greatly sensitive to whether L = 5
or L = 13.
The binding constants between the peptide-MHCI ligand and the TCR are
calibrated by fixing the worst and geometric mean of the binding constants
evolved during a primary response to be 3 × 105 l/mol and 3 × 106 l/mol,
respectively, where the binding constant is related to the energy by
k = ea−bU . (6)
That is, fixing the worst and geometric mean of the binding constants to
these values determines the values of a and b for each instance of the random
parameters with in the generalized NK model. This approach leads to the best
binding constant being on average 3× 107 l/mol. These binding constants are
taken from experiment [19] and are slightly smaller than those for antibodies.
Whenever the peptide substrate is changed, the constants a and b in Eq. 6
are reevaluated by comparison to the existing naive TCR repertoire. All terms
from Eq. 1 are significant, because which of the TCRs from the repertoire best
bind depends on the identity of the peptide.
3 The T Cell Maturation Process
The T-cell-mediated response is driven by cycles of concentration expansion
and selection for better binding constants. Selection processes are ubiquitous
in nature [20], although the exact mechanism of the T cell expansion during
the primary immune response remains elusive. It is clear that the expansion
of the T cells is non-linear [3]. It also seems that, in most cases, there is
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competition among the T cells for the presented antigen [7,21]. Since the T cells
do not mutate during the primary response, our model of the primary response
dynamics to be detailed below can be viewed as one particular description of
the non-linear expansion of the naive T cell repertoire. The primary response
increases the concentration of selected TCRs by 1000 fold over 10 days, with a
rough T cell doubling time of one day. The diversity of the memory sequences
is 0.5% of that of the naive repertoire [2]. The secondary response increases
the concentration of the selected sequences by 10 fold over a few days. For
humans, there are roughly 2.5×107 distinct T cell sequences at a copy number
of 2.4× 104 in the naive repertoire and roughly 1.5× 105 sequences at a copy
number of 2×106 in the memory repertoire [2]. Typical best and worst binding
constants of the memory repertoire are 107 l/mol and 105 l/mol, respectively
[19].
We implement a selection model of the T cell immune system maturation.
Specifically, 10 rounds of selection are performed during the primary response,
with the top x = 58% of the sequences chosen at each round. That is, the
probability of picking one of the sequences for the next round is
Pselect =


1
0.58Nsize
, for U ≤ U∗
0, for U > U∗
(7)
where U∗ is the energy for which 58% of the sequences lie below. This equation
is employed Nsize times, where Nsize is the diversity of the T cell repertoire,
i.e. the number of distinct T cell present within the immune system, to select
randomly the Nsize sequences for the next round. This procedure mimics the
concentration expansion factor of 103 ≈ 210 in the primary response and leads
to 0.5% diversity of the memory repertoire, because 0.5810 ≈ 0.5% and 10
days of doubling leads to a concentration expansion of 210 = 1024.
As discussed in more detail in section 4, the quality of the primary immune
response is often measured experimentally by an in vitro or ex vivo assay. For
an in vivo secondary response, we calculate the average binding constants of
the memory and naive responses, and whichever is larger determines whether
the response will be from the memory or naive repertoires. In fact, the memory
binding constant is multiplied by a factor of 100, as memory T cells are present
at higher concentrations and more broadly present in the tissue than are naive
T cells. If the memory cells are used in the secondary in vivo response, the top
x = 58% of the sequences are chosen, and 3 rounds of selection are performed
[3,4]. This mimics the concentration factor of 10 ≈ 23 during the secondary
memory response. Conversely, if the naive cells are used in the secondary in
vivo response, the dynamics is identical to that of the primary response. For
an in vitro secondary response, in which memory T cells are extracted and
stimulated in an in vitro experiment, 3 rounds of selection are performed,
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starting with exclusively memory sequences.
Implementation of our theory proceeds by computational simulation of the
generalized NK model. First, the peptide and the altered peptide ligands are
created. Then, the random terms such as the secondary structural types of the
subdomains, the σ values, the binding sites, and the interaction sites of the
generalized NK model are determined. Then the fraction and identity of the T
cell repertoire that responds well to the peptide ligand is identified. Typically,
1 in 105 T cells responds well to any particular ligand, and one thus expects
on the order of 108/105 = 1000 T cells to participate in the naive response.
Then the values of the constants a and b in Eq. 6 are calculated. The primary
response of 10 rounds of selection is then carried out. Finally, the secondary
response, either 10 rounds from the naive pool or 3 rounds from the memory
pool, depending on the relative binding constants for the altered peptide is
carried out.
4 Experiments with Altered Peptide Ligands
A fundamental way to measure the correlation between immune responses to
related antigens is to use altered peptide ligands (APLs). In such experiments,
an immune response is first generated to the original peptide. The peptide
antigen is then changed, typically either conservatively or non-conservatively
and only at one amino acid position [22]. The immune response to this al-
tered peptide antigen is then measured. Intuitively, one expects that if the
peptide antigen is altered only slightly, the immune response to the APL will
be relatively high, whereas if the peptide is altered significantly, the immune
response to the APL will be rather low.
Specific lysis is a measure of the probability that an activated T cell will
recognize an antigen presenting cell that is expressing a particular peptide-
MHCI complex. This quantity is measured as a function of the effector to
target ratio, E0/T0, the ratio of the number of T cells to the number of antigen
presenting cells. Each T cell typically expresses on the order of 105 identical
TCRs, and each antigen presenting cell typically expresses on the order of
2 × 104 peptide-MHCI complexes [19]. In typical experiments, the specific
lysis is measured over a 4 hour time period [23]. Although T cells can each
kill many targets in vivo, the experimental specific lysis assay requires the
number of of T cells to be greater than the number of targets for detectable
killing. Lysis is a statistical event, being on average roughly proportional to
the probability of a T cell binding the target cell. To calculate the specific
lysis curve, we calculate the amount of the target cells that are bound by all
T cells. We do this by considering the equilibrium between the effector T cells
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and the target antigen presenting cells:
Ei + T ⇀↽ EiT, Ki . (8)
This equation implies [EiT ]/([Ei][T ]) = Ki. Introducing the amount of antigen
presenting cells that are bound by T cell i, ξi, and noting that the effector
concentration is typically higher than the concentration of antigen presenting
cells, we find
ξi = KiE
0
i (T0 −
∑
i
ξi) . (9)
Summing over all T cells, we find for the total amount of antigen presenting
cells bound by any T cell:
L =
∑
iKiE
0
i
1 +
∑
iKiE
0
i
. (10)
where L =
∑
i ξi/T0 is the specific lysis. Writing this in the form
L =
zE0/T0
1 + zE0/T0
, (11)
we find z = T0
∑
iKiE
0
i /E0 = T0〈K〉. Thus, the competitive binding pro-
cess for the antigen presenting cells can be viewed as a Langmuir adsorption
isotherm of the T cells onto the antigen presenting cells.
The binding constant Ki is that between the two cells. Assuming that the
free energies of binding for each of the TCR/peptide-MHCI interactions are
approximately additive, we find Ki = 10
5×2×104ki, where ki is the molecular
binding constant between TCR i and the peptide-MHCI complex. Typical
values of the target cell concentration are 2 × 103 target cells in 200 µl of
solution, or T0 = 1.66× 10−17M [23]. We, thus, find
z =
〈k〉
3× 107 . (12)
Interestingly, the maximum value of the binding constant in Eq. 6 is of the
same order of magnitude as the denominator in Eq. 12. For convenience, we
have chosen them to be identical. Adding in some cooperativity in the binding,
i.e. assuming that the free energies of binding for each of the TCR/peptide-
MHCI interactions are not entirely additive, will only change details such as
the denominator in Eq. 12.
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At infinite dilution of the T cells, we find that the average number of antigen
presenting cells that are lysed by one T cell is LT0/E0 = z. The quantity
z is, therefore, the average clearance probability of one T cell. Since the T
cell typically can lyse no more than one target cell in specific lysis assays, we
modify the definition of the clearance probability as
z =
1
Nsize
Nsize∑
i=1
min(1, ki/3× 107) . (13)
This equation is implemented by introducing a lower cutoff in the energy
according to 3× 107 = exp(a− bUmin).
The immune response probability is a measure of the probability that the
clearance probability is greater than 50%. In other words, the immune response
probability is the average of H(L− 1/2), where H(x) = 0, x < 0 and H(x) =
1, x > 0. Both the specific lysis and the immune response probability are
averaged over many instances of the random energy model, typically 104.
Both specific lysis and immune response probability can be measured exper-
imentally either in vitro or ex vivo. Typically these responses are measured
after the primary response to the original peptide ligand and before a true
secondary response to the altered peptide ligand. Experimentally, the ex vivo
response is measured by preparing mice, immunizing with the virus, and after
8–10 days removing the spleen of the mouse. The T cells from the spleen are
then challenged with antigen presenting cells expressing the specific altered
peptide ligand. The spleen in this case contains both memory and naive T
cells. For the ex vivo APL response, we use Nsize/2 distinct memory cells and
Nsize distinct naive cells, where Nsize is the diversity of the naive T cell reper-
toire, to calculate the observables [2]. Experimentally, the in vitro response is
measured by removing the spleen of the mouse, immunizing the spleen cells
with the virus, and after 8-10 days challenging those spleen cells with antigen
presenting cells expressing the specific altered peptide ligand. The spleen in
this case contains predominantly memory cells. For the in vitro APL response,
we use exclusively Nsize memory cells to calculate the observables.
We use this theory to analyze the correlations in the immune response that are
measured in altered peptide ligand experiments. The non-linear susceptibility
of the random energy model to structural changes allows us to capture the
correlations in the immune response to altered peptide antigens. An extensive
set of quantitative experiments on altered peptide ligands has been carried out
on the mouse model viral disease lymphocytic choriomeningitis virus (LCMV).
Due to the particularly strong immunogenicity of LCMV, the memory T cell
population is comprised essentially exclusively of T cells from the primary
LCMV response, in contrast to the more typical case where 1-10% of the
memory T cell population is specific for a particular disease [24]. Shown in
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Figure 2 is a comparison between the measured and calculated ex vivo and
in vitro responses to altered peptide ligands with a single non-conservative
mutation. Experiments have been carried out with conservative mutations
as well, and shown in Figure 3 is a comparison between the measured and
calculated ex vivo and in vitro responses to altered peptide ligands with a
single conservative mutation.
The in vitro response is always greater than the ex vivo, because a purely
memory response is better than a naive response for these peptides altered by
one amino acid. The responses are slightly superior for the conservative mu-
tations than for the non-conservative mutations, because in the conservative
case the altered peptide is more similar to the original peptide upon which
the memory sequences were evolved.
Immune response probabilities have not been widely measured. In a classic
study, Klenerman and Zinkernagel found that 1 out of 7 non-conservatively
altered peptides produced a response to LCMV [22]. This data point is shown
in Figure 4. Also shown are the ex vivo and in vitro immune response prob-
abilities to altered peptide ligands with a single non-conservative mutation.
Shown in Figure 5 are the ex vivo and in vitro immune response probabilities
to altered peptide ligands with a single conservative mutation.
The in vitro response remains superior to the ex vivo response, as the pep-
tides with a single amino acid mutation are best recognized by the mem-
ory sequences. In addition, the conservative response is stronger than the
non-conservative response, because the conservatively mutated peptides are
more similar to the native target of the memory sequences than are the non-
conservatively mutated peptides.
5 A Critical Point in the Immune Response Probability
It can be seen that larger repertoire sizes lead to a sharpening of the immune
response probability curve. In fact, there is a critical point in our model which
occurs at E0/T0 = 4.6 for the in vitro and E0/T0 = 16 for the ex vivo case. The
critical immune response probability lies in the range 0.14–0.23. The critical
value of E0/T0 is shifted to a higher value for the ex vivo case because the
average energies are not as favorable in this case. Randomness in the ensemble,
due to the energy fluctuations, causes the immune response probability in the
infinite repertoire limit to be a smooth curve, rather than a step function. Such
randomness would correspond, for example, to the variability in an individual’s
response to a variety of disease strains or the variability in the response of a
population of individuals to a specific disease strain. In our model, there is
an additional source of randomness for a finite repertoire size, the inexact
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evaluation of the constants a and b in Eq. 6. Assuming that the variation
in a is more significant and is Gaussian, we can roughly say z = exp(a +
ασ − bU), where σ is a Gaussian with unit variance and zero mean, α =
O(1/
√
N size) is the rough size in the error of the calculation of a, and U is
random with a certain probability distribution. We calculate the contribution
of the randomness in a to the immune response probability, F , as
∂F
∂α
= 〈∂H
∂L
∂L
∂α
〉
= 〈δ(L− 1/2)∂L
∂z
∂z
∂α
〉
=
1
4
〈σ|L = 1/2〉
=
1
4
∫
dσP (σ)σ
∫
duP (u)δ(L− 1/2)
=
1
b
∫
dσP (σ)σP (u∗)|x exp(a+ασ−bu∗)=1 (14)
Assuming that the randomness in the energy is also Gaussian, we find
F =F0 − α
2
2b2
x(−a+b〈u〉)/(b
2χ)e−[(a−b〈u〉)
2+ln2 x]/(2b2χ)
×a− b〈u〉+ ln x
χ(2πχ)1/2
(15)
where χ = 〈(u − 〈u〉)2〉. The fixed point occurs for x∗ = exp(−a + b〈u〉) and
F ∗ = 1/2. The deviation of the immune response probability from the infinite
repertoire size limit is O(α2) = O(1/Nsize). The shape of this curve is very
similar to that seen in Figures 4 and 5. If we make a more detailed analysis
that takes into account the negative asymmetry of the probability distribution
for ln z, which is due to the cutoff in Eq. (13), we find that F ∗ is lowered from
1/2. The ex vivo probability distribution for ln z is more symmetric than is
the in vitro probability distribution, and so the ex vivo fixed point should be
higher than the in vitro fixed point. In addition, the conservative probability
distribution for ln z has a smaller negative tail than does the non-conservative
distribution, and so the conservative fixed point should be higher than the
non-conservative fixed point. These predictions are in agreement with the
observations in Figures 4 and 5.
6 Correlation in Forward and Reverse APL Experiments
Using our random energy model, it is possible to examine how correlations in
the forward altered peptide ligand experiment give rise to altered correlations
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in the reverse altered peptide ligand experiment. For example in Ref. [22], one
set of experiments was performed with LCMV wild-type as the original peptide
and LCMV-8.7 as the altered peptide ligand, and another set of experiments
was performed with LCMV-8.7 as the original peptide and LCMV wild type
as the altered peptide ligand. In Figure 6, we show these data as well as a
representative set of curves from our theory.
A more systematic way to study such forward and reverse experiments is to
look at the correlation between a response in the forward original peptide
ligand (OPL) → APL experiment and the reverse APL → OPL experiment.
We introduce the correlation matrix
C =

 〈zAzB〉 〈zA(1− zB)〉
〈(1− zA)zB〉 〈(1− zA)(1− zB)〉

 . (16)
Here zA is the in vitro clearance probability of the APL in the forward exper-
iment where the memory sequences were evolved against the OPL, and zB is
the in vitro clearance probability of the OPL in the reverse experiment, where
the memory sequences were evolved against the APL. The averages are taken
over instances of the random energy model. Although the average response
is the same for the forward and reverse experiments, 〈zA〉 = 〈zB〉, there may
be a correlation between the two responses. To specify the notation, we note
that the probability of a forward response is given by P (A) = 〈zA〉 and that
of a reverse response by P (B) = 〈zB〉. The probability of both a forward
and reverse response is given by P (A,B) = 〈zAzB〉 = C11. The conditional
probability that the reverse experiment is successful, given that the forward
experiment is successful, is
P (B|A) = P (A,B)
P (A)
=
P (A,B)
P (B)
=
C11
〈zA〉 . (17)
From our model, we find 〈zA〉 = 0.113 and C11 = 0.01651, and thus P (B|A) =
0.146. These values are not greatly sensitive to the repertoire size. The cross
correlation is given by (∆C)2 = C11 − P (A)P (B) = 0.003797. The cross
correlation can alternatively be expressed as
P (B|A)
P (A)
= 1 +
(
∆C
P (A)
)2
. (18)
If there were no correlation between the two experiments, we would find
P (B|A)/P (A) = 1. If there were complete correlation between the experi-
ments, P (B|A)/P (A) = 1/P (A) = 8.87. In fact, we find in our model that
P (B|A)/P (A) = 1.30, showing a modest amount of correlation between the
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OPL → APL and APL → OPL experiments. Experimental measurements of
this predicted correlation would be very interesting.
7 Summary
The random energy model of the T cell immune system presented here allows
an investigation of the sequence-level evolution that occurs within the T cell
repertoire. This is remarkable, given the complexity underlying the immune
response. Correlations in the immune response to mutated antigens are cap-
tured by the non-linear susceptibility of the underlying random energy model
to structural changes. Specific lysis curves for the model virus LCMV are well
predicted by the theory. The immune response probability is shown to vary in
a systematic fashion with the effector to target ratio, and more experimental
measurements of this quantity are needed.
The effective design of vaccines for viral diseases requires some estimation
of the likely escape mechanisms of the virus. For example, for rapidly mu-
tating strains, a highly-diverse, multicomponent vaccine may be necessary to
halt progression and transmission of the virus. Conversely, for slowly evolv-
ing strains, diversity within the vaccine may simply dilute the conference of
protective immunity. The approach taken here allows investigation and deter-
mination of the fundamental qualitative and quantitative features that govern
the interaction between an effective multicomponent vaccine and the variabil-
ity of the virus. The theory complements and may provide some guidance to
the long and difficult process of experimental multicomponent vaccine devel-
opment against escaping viral diseases.
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Fig. 1. Figure of the interaction between the TCR and the peptide-MHCI com-
plex. The TCR consists of two domains, α and β, each of which contains three
complementary determining regions (CDRs) that interact with the peptide-MHCI
complex. The MHCI complex consists of two domains, α and β, and the α domain is
comprised of two halves, α1 and α2. a) Top view of the peptide-MHCI complex. The
peptide (gray) sits like a “hotdog in a bun” in the α1 and α2 domains of the MHCI
complex (black). b) Side view of CDR 1 (gray) from TCR domain α interacting
with the first few amino acids of the peptide and the MHCI and of CDR 1 (gray)
from TCR domain β interacting with the last few amino acids of the peptide and
the MHCI. The TCR (light gray) sits on top of the peptide-MHCI complex. The
peptide sites between the TCR and MHCI complex. c) CDR 2 (gray) from TCR
domain α interacts with the first few amino acids of the peptide and the MHCI, and
CDR 2 (gray) from TCR domain β interacts with the last few amino acids of the
peptide and the MHCI. d) CDR 3 (gray) from both TCR domains interacts with
the middle few amino acids of the peptide. Atomistic details of this interaction are
from an X-ray crystal structure ([25], http://www.rcsb.org/pdb/, accession number
1AO7). The interactions between the peptide and the TCR are represented by the
last two terms of Eq. 1. The TCR itself must fold, and these terms are represented
by the first two terms of Eq. 1. The interactions between the TCR and the MHCI
complex have been integrated out in the model.
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Fig. 2. Specific lysis as a function of effector to target ratio for repertoire sizes in
the range 103 to 106 for non-conservatively altered peptide ligands. The theoretical
curves overlap for all repertoire sizes. Results are for ex vivo (upper) and in vitro
(lower). Experimental data (circles) are from the LCMV mouse models of [23] (ex
vivo) and [26] (in vitro).
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Fig. 3. Specific lysis as a function of effector to target ratio for repertoire sizes in
the range 103 to 106 for conservatively altered peptide ligands. Results are for ex
vivo (upper) and in vitro (lower). Experimental data (circles) are from the LCMV
mouse models of [22] (ex vivo) and [27] (in vitro).
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Fig. 4. Immune response probability as a function of effector to target ratio for
repertoire sizes of 103, 3× 103, 104, 3× 104, 105, and 3× 105 for non-conservatively
altered peptide ligands. Larger repertoire sizes lead to a greater slope at the inflec-
tion point of the curve. Results are for ex vivo (upper) and in vitro (lower). Exper-
imental datum (horizontal dashed line) is taken from the LCMV mouse model of
[22] (live mouse, in vivo).
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Fig. 5. Immune response probability as a function of effector to target ratio for
conservatively altered peptide ligands. Repertoire sizes as in Figure 4. Results are
for ex vivo (upper) and in vitro (lower).
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Fig. 6. Representative specific lysis curves for a forward and backward altered
peptide ligand experiment. Data from experiments with LCMV-WE original ligand
and LCMV-8.7 altered peptide ligand (circles) and LCMV-8.7 original ligand and
LCMV-WE altered peptide ligand (squares) from the in vitro LCMV mouse model
of [22].
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